NASDAQ, AGEN - Agenus Inc
Antigenics Inc. (including its subsidiaries, also referred to in this Annual
Report on Form 10-K as ?Antigenics?, the ?Company?, ?we?, ?us?, and ?our?) is a
biotechnology company developing technologies and product candidates to treat
cancers and infectious diseases, primarily based on immunological approaches.
Our most advanced product candidate is Oncophage? (vitespen), a patient-specific
therapeutic cancer vaccine candidate that has been tested, or is currently being
tested, in several cancer indications, including in Phase 3 clinical trials for
the treatment of renal cell carcinoma, the most common type of kidney cancer,
and for metastatic melanoma. Oncophage has also been tested in Phase 1 and Phase
2 clinical trials in a range of indications and is currently being tested in a
Phase 1/2 clinical trial in recurrent glioma, or brain cancer. ...
Read SEC Filing on NASDAQ.com »